Leukemia News

Steven A. Rosenberg, MD, PhD, FAACR, will be awarded the 2024 American Association for Cancer Research Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting in San Diego.

More evidence has emerged that T-cell lymphoma following chimeric antigen receptor T-cell therapy is both rare and not necessarily caused by the treatment.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

More than 130,000 cancer cases went undiagnosed during the first 10 months of the COVID-19 pandemic, researchers estimated in a cross-sectional analysis published in JAMA Oncology.

Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.

A COVID-19 diagnosis led to a delay in receiving chemotherapy among younger patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, results from a retrospective analysis published in JAMA Network Open showed.

Mohandas Narla, DSc, may hold the title of American Society of Hematology president, but his focus for the next several months will extend far beyond this country’s borders.

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

The FDA placed a clinical hold on studies evaluating magrolimab for the treatment of acute myeloid leukemia and myelodysplastic syndromes, according to a statement released by the manufacturer.

The combination treatment of two or more antihypertensive therapies in patients being treated with ibrutinib can significantly reduce blood pressure, data published in Blood Advances showed.